On March 16, 2026, Chengdu Kanghua Biological Products Co., Ltd. (stock code: 300841, stock abbreviation: Kanghua Bio) issued an announcement stating that its ACYW135 group meningococcal conjugate vaccine has officially obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, and is authorized to conduct clinical trials against epidemic cerebrospinal meningitis (hereinafter referred to as "meningococcal") caused by meningococcal groups A, C, Y and W135. This marks a core step forward for this domestic vaccine company in the technological upgrading and pipeline improvement of the meningococcal vaccine field.

According to the announcement, the ACYW135 group meningococcal conjugate vaccine, which has been approved for clinical trials, has the application number CXSL2501077, is classified as a Class 3.3 drug, and has the clinical trial approval notice number 2026LP00672. The National Medical Products Administration's approval conclusion indicates that the vaccine meets the relevant requirements for drug registration and approves clinical trials for the corresponding indication. The clinical trials must be conducted within three years from the date of approval; if informed consent forms for the subjects are not signed within this period, the notice will automatically become invalid.
Meningococcal meningitis is an acute respiratory infectious disease caused by meningococcal infection. Severe cases can present with purulent meningitis, sepsis, and other serious clinical manifestations, with a high mortality rate and risk of sequelae. It is one of the key infectious diseases to be controlled in the global public health field. Publicly available epidemiological data shows that meningococci are divided into 13 serogroups, of which serogroups A, B, C, W135, and Y cause approximately 95% of meningococcal meningitis cases worldwide. The quadrivalent meningococcal vaccine is the core prevention and control tool that covers the mainstream pathogenic serogroups.
From a technical perspective, the product for which Kanghua Bio has received clinical trial approval utilizes a conjugate vaccine technology and is intended for vaccination of the entire population aged 2 months and older. Compared to traditional polysaccharide vaccines, conjugate vaccines effectively address the industry pain point of insufficient immunogenicity of polysaccharide vaccines in infants under 2 years old, providing more effective immune protection for young children, a key population susceptible to meningococcal meningitis. Kanghua Bio stated in its announcement that the vaccine covers the main pathogenic serogroups of meningococcal meningitis and exhibits good immunogenicity. If its development is successful and it is approved for market launch, it will provide a more comprehensive immunization strategy for young children and key populations.
From a global and domestic market perspective, the ACYW135 group meningococcal conjugate vaccine market has long been dominated by multinational pharmaceutical companies. Major overseas manufacturers include the three giants: GlaxoSmithKline (UK), Pfizer (USA), and Sanofi Pasteur (France). Currently, one company in the domestic market has had its similar quadrivalent meningococcal polysaccharide conjugate vaccine approved for marketing. Kanghua Bio's entry will add another important market participant to the domestic quadrivalent meningococcal conjugate vaccine market.
It is worth noting that the quadrivalent meningococcal conjugate vaccine, which has now been approved for clinical trials, will create a significant product synergy with Kanghua Bio's already marketed ACYW135 group meningococcal polysaccharide vaccine. Industry analysts point out that the domestic meningococcal vaccine market is currently in a critical period of upgrading from polysaccharide vaccines to conjugate vaccines. By adopting a dual-product strategy of "polysaccharide + conjugate," Kanghua Bio can achieve full coverage of all technical routes and all age groups in the meningococcal vaccine field, further improving its product matrix in the bacterial vaccine field and forming a differentiated market competitiveness.
Regarding the impact of this clinical trial approval on the company, Kanghua Bio stated in its announcement that the approval will not have a significant impact on the company's short-term financial condition and operating performance; if the vaccine is successfully developed and eventually approved for market launch, it will effectively enrich the company's vaccine product pipeline, enhance the company's core competitiveness, and have a positive significance for the company's long-term sustainable development.
At the same time, Kanghua Bio also issued a related R&D risk warning. The announcement emphasized that vaccine products are characterized by long R&D cycles, high technical difficulty, and high R&D risks. Coupled with factors such as changes in the external market environment, there is still some uncertainty as to whether the vaccine's R&D results can be successfully mass-produced and marketed. The company will continue to advance the clinical research of the vaccine and strictly comply with regulatory requirements, fulfilling its information disclosure obligations in a timely manner according to the R&D progress.
As innovation and upgrading in China's vaccine industry continue to deepen, technological iteration and market competition in the meningococcal vaccine field have entered a new stage. The approval of Kanghua Bio's quadrivalent meningococcal conjugate vaccine for clinical trials is not only a significant breakthrough for the company's own pipeline development, but will also provide more product reserves for the improvement of China's meningococcal prevention and control system. The subsequent progress of its clinical trials will continue to receive close attention from the industry and the market.

https://mp.weixin.qq.com/s/TGUKcLfKMP9aQK9CObcnPw